AlzChem Group AG
- WKN: A2YNT3
- ISIN: DE000A2YNT30
- Land: Deutschland
Nachricht vom 06.05.2020 | 09:44
AlzChem Group AG: AlzChem to supply components for corona tests
AlzChem to supply components for corona tests
For many years AlzChem has been reliably supplying various pharmaceutical companies with the two intermediate products guanidine hydrochloride and guanidine thiocyanate. Both are now also used to manufacture the corona tests that are currently in great demand worldwide. In order to avoid raw material bottlenecks, AlzChem has greatly increased its production capacities for guanidine hydrochloride and guanidine thiocyanate by making a significant investment in short-term financial resources and manpower. "Business is only one aspect of this - it is at least as important for us to do our part in combating the pandemic in this global crisis. We want to do everything we can to improve the health situation of as many people as possible," emphasizes Dr. Georg Weichselbaumer, member of the Executive Board and CSO of AlzChem.
Particularly when used in combination and widely deployed, the two types of tests - the detection of viruses and the detection of antibodies - can provide a relatively accurate picture of how the infection is progressing. For those responsible to make well-founded decisions, it is particularly important to not only know how many people have been infected with SARS-CoV-2 since the tests began. The number of patients who have recovered from it is also of immense importance, as this is the only way to determine the number of people currently infected. Whether someone was infected can only be determined by detecting antibodies. A large number of pharmaceutical companies are working to make such tests available reliably and in sufficient quantities.
The AlzChem Group is a vertically integrated manufacturer of chemical products based on the so-called NCN chain. These are products with a typical nitrogen-carbon-nitrogen bond that are used in a wide range of industries, including the pharmaceutical industry, which is supplied by AlzChem with intermediate products not only for corona tests, but also for the production of vital drugs for the treatment of diabetes II, AIDS and heart disease, among other conditions.
End of Media Release
Issuer: AlzChem Group AG
Key word(s): Research/Technology
|Company:||AlzChem Group AG|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart|
|EQS News ID:||1037045|
|End of News||DGAP Media|
Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv
Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.
Der AKTIONÄR News
08. August 06:30 Munich Re: Beirut-Schock gut verdaut
07. August 18:42 DAX, Dow & Co mit starker Woche – T-Mobile US und Biogen ...
07. August 15:32 AKTIONÄR-Tipp Nautilus: Stark wie Arnie
News im Fokus
Henkel AG & Co. KGaA: Henkel mit robuster Geschäftsentwicklung trotz starker Belastungen durch COVID-19-Pandemie
06. August 2020, 07:34
Webcast Q2 Results 2020
14. August 2020
Original-Research: Adler Modemärkte AG (von Sphene Capital GmbH): Buy
07. August 2020